Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Advertisement

EU approves FREHEMGO (denecimig) for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing – Novo

Written by | 20 Nov 2026 | Drug Approvals

Novo announced that the European Commission has granted marketing authorisation for FREHEMGO (denecimig) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A (congenital FVIII deficiency), with or without inhibitors.
The authorisation follows the positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency in September 2026.

FREHEMGO is a next-generation FVIIIa mimetic bispecific antibody given as an injection under the skin. People with haemophilia A, with or without inhibitors, and their healthcare teams can choose between once-monthly, once-every-two-weeks or once-weekly dosing, using a single-use pre-filled pen.

“Living with haemophilia means constantly planning around the risk of bleeding, often from early childhood. Each advance in treatment gives people with haemophilia and their families more freedom to focus on other aspects of life” said Maria Elisa Mancuso, Medical Member of the Board of Directors of World Federation of Hemophilia (WFH) and Senior Hematology Consultant at the Centre for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital in Rozzano, Milan, Italy. “Having more treatment options to discuss with their clinicians allows people to consider what best fits their everyday lives—at school, at work, in sport and within their families—and make informed decisions that reflect their individual needs and priorities.”

The approval is based on results from the FRONTIER clinical trial programme. In the pivotal FRONTIER2 trial, denecimig significantly reduced annualised bleeding rates compared with prior clotting factor prophylaxis and on-demand treatment in people with haemophilia A, with or without inhibitors. In children younger than 12 years, results from FRONTIER3 were consistent with the efficacy seen in adolescents and adults. Across the FRONTIER programme, denecimig has shown consistently low mean annualised bleeding rates, with a substantial proportion of participants experiencing zero treated bleeds. In the FRONTIER5 trial, direct switching from emicizumab to denecimig showed no new safety signals, a clear preference for the denecimig pen over previous administration methods and a sustained increase in thrombin generation into the normal range over the treatment period, without causing thrombin levels that might pose a thrombotic risk.

“This approval reflects the strength and consistency of the FRONTIER programme, which showed strong bleed protection across adults and children, with and without inhibitors,” said Martin Holst Lange, Chief Scientific Officer and Executive Vice President of Research & Development at Novo. “It’s the result of many years of work by our scientists, the trial investigators and the people with haemophilia A who took part in our studies. Together, they have helped bring the haemophilia community a treatment option that minimises trade-offs in care.”

FREHEMGO has also been approved in Saudi Arabia and is under review by the FDA and other regulatory authorities.

About the FRONTIER trials
The FRONTIER clinical programme includes FRONTIER1-5 and investigates denecimig as a prophylactic treatment to prevent bleeding episodes across paediatric and adult populations with haemophilia A, with or without inhibitors. FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the denecimig Marketing Authorisation Application (MAA) submission. FRONTIER2 evaluated denecimig treatment once every month and once every week in adults and adolescents 12 years of age and older; FRONTIER3 evaluated denecimig treatment once every month and once every week in children below the age of 12; FRONTIER4 was an open-label extension trial evaluating the efficacy of denecimig once every two weeks (Q2W) as well as investigating the long-term safety of denecimig across all dosing regimens (once every month, once every two weeks, and once every week) in subjects with haemophilia A, with or without inhibitors.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.